Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study -.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples